Moderna (NASDAQ:MRNA) Given “Hold” Rating at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Moderna (NASDAQ:MRNA) in a research report released on Friday, Benzinga reports.

A number of other research analysts also recently issued reports on the company. The Goldman Sachs Group decreased their price objective on Moderna from $204.00 to $178.00 and set a buy rating for the company in a report on Friday, August 2nd. HSBC raised shares of Moderna from a reduce rating to a hold rating and set a $82.00 price target for the company in a research note on Wednesday, August 28th. Royal Bank of Canada cut shares of Moderna from an outperform rating to a sector perform rating and reduced their target price for the stock from $125.00 to $90.00 in a report on Monday, August 5th. Piper Sandler lowered their price target on shares of Moderna from $157.00 to $115.00 and set an overweight rating on the stock in a research note on Friday. Finally, Barclays reduced their price objective on shares of Moderna from $168.00 to $155.00 and set an overweight rating for the company in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Moderna has a consensus rating of Hold and an average target price of $103.93.

Moderna Stock Performance

Shares of MRNA opened at $69.17 on Friday. The firm has a market cap of $26.51 billion, a P/E ratio of -4.41 and a beta of 1.67. Moderna has a twelve month low of $62.55 and a twelve month high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The firm’s 50 day moving average price is $94.12 and its two-hundred day moving average price is $111.72.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm’s revenue was down 29.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($3.62) EPS. On average, analysts forecast that Moderna will post -9.52 EPS for the current fiscal year.

Insider Buying and Selling

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the transaction, the director now directly owns 2,284,015 shares of the company’s stock, valued at $290,572,388.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total value of $1,908,300.00. Following the sale, the director now directly owns 2,284,015 shares of the company’s stock, valued at $290,572,388.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,158 shares of company stock valued at $11,167,312. 15.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MRNA. Cedar Wealth Management LLC grew its stake in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Commerzbank Aktiengesellschaft FI grew its position in shares of Moderna by 1.7% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after purchasing an additional 93 shares in the last quarter. CVA Family Office LLC increased its holdings in shares of Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after purchasing an additional 96 shares during the period. Claro Advisors LLC raised its position in shares of Moderna by 2.0% in the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after buying an additional 108 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after buying an additional 116 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.